MMedXYNews
HomeVideos
MedXY AI/MedXY News/Tag: HELIOS-B trial
MedXY News
EnglishTag

HELIOS-B trial

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationcritical carebiomarkersartificial intelligencetype 1 diabetesclinical trialsHypertensiononcologyCardiologyMortalitypublic healthcardiovascular diseasediabetesAlzheimer's diseasebreast cancerepidemiology

Latest news

Tag

Consistent Efficacy of Vutrisiran in Transthyretin Cardiac Amyloidosis Amidst Concomitant Disease-Modifying Therapies
CardiologyDisease-Modifying TherapyHELIOS-B trial

Consistent Efficacy of Vutrisiran in Transthyretin Cardiac Amyloidosis Amidst Concomitant Disease-Modifying Therapies

By MedXY|Sep 2, 2026

The HELIOS-B trial demonstrates that vutrisiran significantly reduces mortality and cardiovascular events in ATTR-CM patients, with its efficacy unaffected by concurrent use of tafamidis or heart failure medications, supporting its broad th

Right Ventricular Function, Clinical Outcomes, and Effect of Vutrisiran in Transthyretin Amyloidosis With Cardiomyopathy: Insights from the HELIOS-B Trial
Cardiology
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
HELIOS-B trial
right ventricular dysfunction

Right Ventricular Function, Clinical Outcomes, and Effect of Vutrisiran in Transthyretin Amyloidosis With Cardiomyopathy: Insights from the HELIOS-B Trial

By MedXY|Aug 27, 2026

This review synthesizes evidence on the prevalence and prognostic value of right ventricular dysfunction in ATTR-CM and the therapeutic impact of vutrisiran on RV function from the HELIOS-B trial, underscoring RV free wall strain as a key b

Left Atrial Dysfunction and Vutrisiran Efficacy in Transthyretin Amyloid Cardiomyopathy: Insights from the HELIOS-B Trial
Cardiologyleft atrial dysfunctioncardiomyopathy

Left Atrial Dysfunction and Vutrisiran Efficacy in Transthyretin Amyloid Cardiomyopathy: Insights from the HELIOS-B Trial

By MedXY|Aug 21, 2026

This article reviews the prognostic role of left atrial dysfunction in transthyretin amyloid cardiomyopathy and evaluates vutrisiran’s impact on atrial function and clinical outcomes based on a secondary analysis of the HELIOS-B phase 3 tri

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Cardiology
Precision Medicine for Long QT Syndrome Type 2: Lumacaftor Corrects Trafficking Defects and Shortens QT Interval
General Surgery
Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models